Zusammenfassung

Ziel: Der Nutzen einer i.v.-Thrombolyse bei akuten ischämischen Schlaganfall mit hoher Thrombuslast ist begrenzt. Eine erfolgreiche Rekanalisation durch die i.v.-Thrombolyse wird äußerst unwahrscheinlich, wenn die Thrombuslänge 7 mm übersteigt. Die vorliegende retrospektive Studie soll daher den Nutzen und die Sicherheit der Neurothrombektomie mittels des Trevo®-Stentretreivers in der Behandlung des akuten embolischen Schlaganfalles an Patienten mit einer Thrombuslänge von ≥ 8 mm prüfen.

Material und Methoden: 40 Patienten mit einem akuten Verschluss eines vorderen intrakraniellen Hirngefässes und einer Thrombuslänge von ≥ 8 mm wurden mittels Neurothrombektomie behandelt. Es wurde das klinische Ergebnis mit einer historischen Kontrollgruppe aus 42 Patienten mit einer Thrombuslänge von ebenfalls ≥ 8 mm verglichen, welche nur mit einer i.v.-Thrombolyse behandelt wurden. In beiden Gruppen wurde von einem unabhängigen Prüfer das klinische Ergebnis anhand der modifizierten Rankin-Skala (mRS) bei Entlassung und nach 90 Tagen bestimmt.

Ergebnisse: Die Patienten unterschieden sich nicht bezüglich Alter, mRS auf Aufnahme, Thrombuslänge oder der Zeit vom Symptombeginn bis Beginn der i.v.-Thrombolyse, jedoch wies die Thrombektomie-Gruppe einen höheren NIHSS bei Aufnahme auf. Eine erfolgreiche Rekanalisation wurde in 33/40 Patienten (83 %) mit der Neurothrombektomie erreicht. 15 Patienten erhielten eine i.v.-Thrombolyse vor der Neurothrombektomie. Der mediane mRS bei Entlassung betrug 3,5 (1,25 – 5) vs. 5 (4 – 6; p < 0,01) und an Tag 90 3 (1 – 4) vs. 5 (4 – 6; p < 0,01). Symptomatische intrakranielle Blutungen traten in 3 vs. 7 Patienten auf, 3 vs. 17 Patienten starben innerhalb von 90 Tagen (je Thrombektomie vs. Kontrolle). Es zeigten sich nur wenige intervention-bezogene Komplikationen.

Abstract

Purpose: The efficacy of i.v. thrombolysis in acute stroke with high clot burden is limited. Successful recanalization is very unlikely if the thrombus length exceeds 7 mm. Thus this retrospective controlled study evaluated the efficacy and safety of neurothrombectomy in the treatment of acute embolic stroke in patients selected by a thrombus length of ≥ 8 mm using the stent retriever Trevo® device.

Materials and Methods: 40 patients with acute occlusion of the anterior intracranial arteries with a thrombus length of ≥ 8 mm were treated with neurothrombectomy. We compared the outcome with a historical cohort of 42 patients with a thrombus length of ≥ 8 mm that received i.v. thrombolysis only. Clinical outcome was assessed by modified Rankin scale in both groups at discharge and on day 90.

Results: Patients did not differ in age, mRS on admission, thrombus length or time from symptom onset to i.v. thrombolysis, but the thrombectomy group had higher NIHSS on admission. Successful recanalization was achieved in 33/40 patients (83 %) with neurothrombectomy. 15 patients received i.v. thrombolysis prior to neurothrombectomy. Median mRS at discharge was 3,5 (1,25 – 5) vs. 5 (4 – 6; p < 0,01) and on day 90 3 (1 – 4) vs. 5 (4 – 6; p < 0,01). Symptomatic hemorrhage occurred in 3 vs. 7 patients. 3 vs. 17 patients died within 90 days (thrombectomy vs. control each). There were only a few intervention-related complications.

Conclusion: Thrombectomy in acute stroke with high clot burden using the Trevo® device has a low risk and improved clinical outcome compared to i.v. thrombolysis alone. Treatment selection by a clot length of ≥ 8 mm might be a powerful approach to improve the outcome of mechanical thrombectomy.
Schlussfolgerung: Eine Thrombektomie mit dem Trevo®-Device bei akutem Schlaganfall mit hoher Thrombuslast hat ein geringes Risiko und verbessert das klinische Ergebnis im Vergleich zur alleinigen Thrombolysie. Eine Indikationsstellung zur Thrombek- 
Risiko und verbessert das klinische Ergebnis im Vergleich zur
bei akutem Schlaganfall mit hoher Thrombuslast hat ein geringes

Key Points:
▶ Clot length of ≥ 8 mm might be a valuable criterion for indicating neurothrombectomy.
▶ Thrombectomy using the Trevo® device is safe and effective.

Citation Format:

Table 1 Patient characteristics at baseline.

<table>
<thead>
<tr>
<th>characteristics</th>
<th>neurothrombectomy</th>
<th>thrombolysis only</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>number of patients, n</td>
<td>40</td>
<td>42</td>
<td>—</td>
</tr>
<tr>
<td>sex</td>
<td>n</td>
<td>age</td>
<td>NIHSS</td>
</tr>
<tr>
<td>sex, n, male:female (%)</td>
<td>13:27 (33 vs. 68 %)</td>
<td>21:21 (50 vs. 50 %)</td>
<td>0.15</td>
</tr>
<tr>
<td>age, y</td>
<td>71 (54–76)</td>
<td>72.5 (66–80)</td>
<td>0.05</td>
</tr>
<tr>
<td>NIHSS</td>
<td>14 (12–20)</td>
<td>13 (10–16)</td>
<td>—</td>
</tr>
<tr>
<td>right:left, n</td>
<td>16/24</td>
<td>20/22</td>
<td>—</td>
</tr>
<tr>
<td>ICA-T, n</td>
<td>13</td>
<td>10</td>
<td>—</td>
</tr>
<tr>
<td>MCA-M1, n</td>
<td>26</td>
<td>30</td>
<td>—</td>
</tr>
<tr>
<td>MCA-M2, n</td>
<td>1</td>
<td>2</td>
<td>—</td>
</tr>
<tr>
<td>thrombus length, mm</td>
<td>13 (10–20)</td>
<td>12.4 (9–17)</td>
<td>0.22</td>
</tr>
<tr>
<td>rtPA, n</td>
<td>15 (37.5 %)</td>
<td>42 (100 %)</td>
<td>—</td>
</tr>
<tr>
<td>time from symptom onset to IVT, min</td>
<td>118 (98–151)</td>
<td>133 (104–166)</td>
<td>0.89</td>
</tr>
<tr>
<td>time from symptom onset to admission at our site, min</td>
<td>148 (58–259)</td>
<td>70 (55–90)</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

M1 / M2, M1 / M2 segment of middle cerebral artery; ICA-T carotid T; IVT i. v. thrombolysis. Time from onset to i. v. treatment: Patients were allocated from external hospitals and partially received i. v. thrombolysis before admission at our site.

1 Data are presented as median (interquartile range).
64-detector row CT scanner (Brilliance 64; Philips, Best, The Netherlands) with a tube voltage of 120 kV and a tube current of 320 mAs, an incremental scanning mode and a smooth reconstruction kernel. Measurements were done by an experienced neuroradiologist blinded to the patient data using the EMPR 3D plugin postprocessing capability of the IMPAX® EE PACS workstation (AGFA® Health Care N.V., Mortsel, Belgium). With this plugin, a 3D curved line was drawn along the HMCAS for measurement of the thrombus length in each patient. Occlusion of the artery was then verified by contrast-enhanced CT angiography.

**Acute stroke management**

Patients eligible for i.v. thrombolysis (n = 15 in the thrombectomy group, all in the control group) were treated with intravenous rtPA (0.9 mg/kg, max. 90 mg; Actilyse®; Boehringer Ingelheim, Germany) within 4.5 hours after symptom onset according to the European guidelines for stroke treatment [3]. Patients eligible for thrombectomy were treated using a bridging concept with i.v. thrombolysis followed by the angiographic procedure which was initiated within 8 hours after symptom onset. 25 patients were treated exclusively with mechanical thrombectomy. Intravenous GP2b3a antagonists were given in 4 patients due to additional stenting of internal carotid artery stenosis and due to stenting of an MCA stenosis in one case.

**Mechanical thrombectomy**

Prior to mechanical thrombectomy, patients were evaluated by non-contrast-enhanced incremental CCT as described above followed by CT perfusion and CT angiography. All patients received general anesthesia. A flexible 6F sheath (Super Arrow-Flex®; Arrow International, Inc.; Reading, PA, USA) was placed into the proximal internal carotid artery via a transfemoral approach. In all patients, a distal guiding/aspiration catheter (either DAC® 057, iDAC® 070 (Concentric Medical, Inc.; Mountain View, CA, USA) or ReFlex® A+058 (Reverse Medical Corporation; Irvine, CA, USA)) was used for clot aspiration. Using a 2.7F 0.021” microcatheter (Trevo® Pro 18; Concentric Medical Inc.; Mountain View, CA, USA), the Trevo® stent retriever was released penetrating the thrombus and was left there for three to five minutes. Clot retrieval was combined with aspiration through a 20 cc syringe. The procedure was repeated when necessary and the TICI score was recorded prior to and after thrombectomy.

**Treatment evaluation**

Successful vessel recanalization by thrombectomy was defined by a recanalization rate of TICI 2b or 3 confirmed by angiography. The clinical status was scored using the NIHSS and modified Rankin Scale (mRS) on admission, mRS at discharge from hospital, and on day 90. The latter was accessible through a regional prospective stroke registry, in which the data was acquired by a neuroradiologist blinded to the patient data using the EMPR 3D construction kernel. Measurements were done by an experienced neuroradiologist blinded to the patient data using the EMPR 3D plugin postprocessing capability of the IMPAX® EE PACS workstation (AGFA® Health Care N.V., Mortsel, Belgium). With this plugin, a 3D curved line was drawn along the HMCAS for measurement of the thrombus length in each patient. Occlusion of the artery was then verified by contrast-enhanced CT angiography.

**Statistics**

Data are presented as median and interquartile range. For group data comparison the Mann-Whitney U-test was used. P-values < 0.05 were regarded as statistically significant. Pearson correlation was used to assess correlations between time to revascularization and clinical outcome (mRS). χ²-test was used to assess significant differences in frequencies.

**Results**

**Demographic and clinical baseline data**

The demographic and clinical data are shown in Table 1. Groups (thrombectomy vs. i.v. thrombolysis) differed in NIH-SS on admission (14 [12–20] vs. 13 [10–16]; p = 0.05), but did not differ in age, mRS on admission (Fig. 1) and thrombus length. The groups differed significantly in the time from symptom onset until the time of admission (148 min [58–259] vs. 70 min [55–90]; p = 0.001), because some patients for thrombectomy were referred from other hospitals. There was no difference concerning the time from symptom onset to i.v. thrombolytic therapy (118 min [98–151] vs. 133 min [104–166]).

**Angiographic outcome and safety**

The mean duration from admission to the start of angiographic interventions was 101 min (81–144). Successful recanalization was achieved in 33 patients (83 %). The time from symptom onset to recanalization was 309 min (248–395) (Fig. 2). The following procedure-related complications occurred: In one patient with M1 occlusion receiving i.v. thrombolysis prior to mechanical recanalization, a symptomatic intracranial hemorrhage occurred within 24 hours. The patient reached good recovery (mRS 2) after 90 days. In another patient embolization of the initially unaffected anterior cerebral artery occurred during successful recanalization of an M1 occlusion. In one patient the advancing microcatheter perforated the target vessel distal to an M1 thrombus. The procedure was terminated and the patient remained asymptomatic for the resulting subarachnoid hemorrhage.

**Clinical outcome**

The median mRS at discharge was significantly better in the thrombectomy group compared to the control group (3.5 [1.25–5] vs. 5 [4–6], p < 0.001) and remained better on day 90 (3 [1–4] vs. 5 [4–6], p < 0.001) (Table 3, Fig. 2, 3). There was no improvement of mRS from admission to discharge in 7 (18 %) thrombectomy patients and 24 (57 %) patients of the control group (p < 0.01). On day 90, 17 of the 40 patients (43 %) having been treated with thrombectomy presented a slight disability (mRS ≤2), but only 2 of the 42 patients (5 %) in the control group. The time to revascularization did not correlate with the...
Clinical improvement assessed with the mRS ($r = -1.9$; $p = 0.1$). After thrombectomy three patients died within 90 days (8 %), while 17 patients (41 %) died in the control group. Symptomatic intracerebral hemorrhage occurred in 3 (8 %) vs. 7 (17 %) patients. 4 vs. 0 patients showed mild non-symptomatic subarachnoid hemorrhage ($p < 0.05$). In the thrombectomy group 3 patients with hemorrhage and 1 patient with subarachnoidal hemorrhage received thrombolytic therapy within the bridging regime.

Discussion

In this study we compared mechanical neurothrombectomy in patients with a high clot burden to a control group treated with i. v. rtPA thrombolysis alone. Clot burden is a major factor for clinical outcome in acute embolic stroke [4] and accordingly thrombus length is a main factor for recanalization after i. v. thrombolysis [1]. Assessment of thrombus length is easily implemented in routine stroke CT scanning without relevant further time consumption. Furthermore, the success of recanalization is a critical factor for clinical outcome after acute embolic stroke. In patients with a thrombus length of more than 8 mm, i. v. thrombolysis achieved recanalization in less than 1 % [1] and usually results in a poor clinical outcome. Accordingly, only 5 % of the patients in our control group reached the favorable outcome of mRS ≤ 2. In this study we found a much better outcome of the mechanical thrombectomy group with regard to survival and disability at 90 days and an acceptable risk profile of the intervention.

Our data show that mechanical thrombectomy using the Trevo® device in acute stroke of the anterior circulation is highly effective. The intervention using the Trevo® device showed a remarkably high rate of successful recanalization (TICI 2b or 3) in 83 %. This exceeds the recanalization rates of the Merci trials (69.5 %, TIMI II-III) [5], (44 %)[6], the IMS-III trial (41 %)[7], the MR RESCUE trial (27 %)[8] and the recently published MR CLEAN trial (58.7 %)[9], which was the first positive RCT on intraarterial treatment against standard stroke treatment. Comparable results have been published by other retrospective trials using the Penumbra system (81.6 %, TIMI II-III) [10], the Solitaire device (90 %, 79 %) [11, 12], the Revive® device (100 %, n = 10) [13], the Trevo® device (68 %, 39 %, 78.3 %) in three trials [6, 14, 15] and using the Trevo® or Solitaire® device (83.9 %, TICI 2a or 3) in the

Table 3  Clinical outcome and safety data.

<table>
<thead>
<tr>
<th>characteristics</th>
<th>neurothrombectomy</th>
<th>thrombolysis only</th>
<th>$p$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRS at discharge$^1$</td>
<td>3.5 (1.25 – 5)</td>
<td>5 (4 – 6)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>mRS after 90 days$^1$</td>
<td>3 (1 – 4)</td>
<td>5 (4 – 6)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>mRS ≤ 2 at 90 days, n (%)</td>
<td>17 (43 %)</td>
<td>2 (5 %)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>death in hospital, n (%)</td>
<td>1 (2.5 %)</td>
<td>11 (26 %)</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>death in 90 days, n (%)</td>
<td>3 (8 %)</td>
<td>17 (41 %)</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>no clinical improvement, n (%)</td>
<td>7 (18 %)</td>
<td>24 (57 %)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>symptomatic ICH, n (%)</td>
<td>3 (8 %)</td>
<td>7 (17 %)</td>
<td>0.21</td>
</tr>
<tr>
<td>non-symptomatic SAH, n (%)</td>
<td>4 (10 %)</td>
<td>0 (0 %)</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

$^1$ Data are presented as median (interquartile range)
case of Pagola et al. [16]. Thus, there is good evidence that mechanical thrombectomy using stent retrievers achieves high rates of successful recanalization. However, none of these previous studies assessed thrombus length.

The clinical outcome was also favorable after thrombectomy. 43% of the patients lead an independent life (mRS ≤ 2) compared to 5% in the control group despite the more severe stroke on admission in the thrombectomy group. In our study mortality seems to be reduced by thrombectomy as well, as indicated by a decrease from 41% to 8%. Previous studies compared intraarterial thrombectomy to standard stroke treatment in acute stroke patients. Three randomized controlled trials failed to show clinical benefit by intraarterial treatment [7, 8, 17]. The inclusion criteria are discussed as a reason for this failure, but the main factor seems to be the low recanalization rate of 27% to 41% in the IMS-III and MR RESCUE trial. This may be due to the infrequent use of stent retrievers or the usage of old recanalization devices in these studies. For example, in the IMS-III trial, only 4 patients were treated with stent retriever devices. Furthermore, in the SYNTHESIS trial and IMS-III trial, no demonstration of large artery occlusion was required. Therefore, the cohorts of these studies are not comparable to the patients analyzed in our study. The randomized controlled MR CLEAN trial [9] very recently proved a clinical benefit of intraarterial treatment compared to standard stroke treatment. Occlusion of the distal internal carotid artery, the middle cerebral artery (M1, M2) or anterior cerebral artery (A1, A2) was required for inclusion and thrombectomy was carried out using a stent retriever in 81.5% of the cases. Thus, the findings of the MR CLEAN trial are in accordance with the results of our study, but thrombus length was not assessed in that trial. However, the clinical and procedural outcome in our study even exceeds the results of the MR CLEAN trial and, in contrast, significant reduction of mortality could be observed in our study. Thus, patient identification by thrombus length, not only the site of occlusion, and solely the use of highly effective stent retrievers seem to be important corner points for successful intraarterial treatment. Once more, registry studies in acute stroke using stent-based thrombectomy also revealed an increase in favorable outcome after 90 days; Leker et al. found up to 60% of patients treated by thrombectomy reaching an mRS of 0 to 2 compared to 37.5% in patients treated by i.v. thrombolysis [18]. In a recent study a 90-day favorable outcome of even 77% and a recanalization rate of 90% could be achieved using the Solitaire® device [19]. Thus, the application of different thrombectomy devices may be the reason for the controversial findings since stent retriever devices showed higher recanalization rates and higher clinical improvement in comparison with other devices [6, 11, 14, 19–23]. We conclude that the significantly higher rate of favorable outcome in patients treated with neurothrombectomy in comparison to patients treated with i.v. thrombolysis alone is caused both by the usage of a stent retriever device for mechanical thrombectomy and patient selection based on the criterion of thrombus length. This might be a very robust criterion indicating neurothrombectomy rather than site of occlusion only.

We had three serious complications among 40 patients which finally led to death in one, poor outcome in another and a favorable outcome in another. We consider this an acceptable risk because of the high mortality in this cohort of stroke patients. However, the complication rate was even lower in the neurothrombectomy group compared to i.v. thrombolysis only. In addition, the incidence of symptomatic intracranial hemorrhages after thrombectomy is not higher than with systemic thrombolysis alone. A higher rate of non-symptomatic subarachnoid hemorrhages in the thrombectomy group might be consistent with reperfusion injury after large vessel recanalization. However, the complication rate seems to be lower than with other thrombectomy devices but head-to-head studies are needed. Furthermore, the four randomized controlled trials [7–9, 17] on intraarterial treatment found no increase in severe adverse events even though three of them did not show superiority of intraarterial treatment. Thus, mechanical thrombectomy seems to be safe in patients with and without previous intravenous thrombolysis.

### Conclusion

Patient selection for neurothrombectomy by thrombus length in acute stroke patients and implementation of stent retriever devices for neurothrombectomy provided a clinically highly effective and technically safe method for successful recanalization with an acceptable risk while patients with a comparable clot burden treated with i.v. thrombolysis only had a low probability of reaching a favorable clinical outcome and showed a high rate of mortality. Our study had an even better result than the MR CLEAN study but it was retrospective and open. Nevertheless, a clot length of at least 8 mm seems to be an additional valuable criterion for indicating neurothrombectomy in acute stroke patients and our results may guide future randomized controlled trials with comparison of neurothrombectomy with systemic thrombolysis only in patients with a thrombus length of more than 7 mm, since recently published controlled trials have not implemented such a criterion. However, further controlled clinical trials on clinical efficacy and safety are warranted and, like the THERAPY trial [NCT01 429 350], are on the way.

### Clinical relevance of the study

- Increasing evidence supports neurothrombectomy in addition to standard stroke treatment in acute embolic stroke.
- Patients with severe acute stroke syndromes should be carefully evaluated regarding high clot burden and should be considered for neurothrombectomy.
- Not only site of occlusion but also thrombus length should be taken into account when thrombectomy is considered.
- Thrombectomy in patients with a high clot burden using the Trevo® stent retriever seems to be safe and effective.

### Affiliations

1. Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany
2. Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Kiel, Germany
3. Department of Radiology, FEK Neumünster, Germany
4. Department of Neurology, Imland Klinik, Rendsburg, Germany
5. Department of Neurology, Klinikum Itzehoe, Germany
6. Department of Internal Medicine, Klinik Preetz, Germany
7. Department of Neurology, DRK Kliniken Berlin, Berlin, Germany
8. Department of Neurology, Helios Klinik, Schleswig, Germany

References


